Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhGH vs rhIGF-1 in Adult Growth Hormone Deficiency
NCT00684957Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Jan 2008
- Primary completion
- Oct 2012
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mecasermin in growth hormone deficiency (GHD) (2 arms), sponsored by Columbia University. Primary endpoint: Cardiovascular Serum Risk Markers Including Lipids, IL-6, CRP and Homocysteine at 2 months. Started Jan 2008; status: terminated.
02
Drugs
mecasermin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT00684957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00684957.